Tectonic Therapeutic (TECX) Cash from Financing Activities (2017 - 2026)
Tectonic Therapeutic (TECX) posted quarterly Cash from Financing Activities of $847000.0 for Q1 2026, down 99.52% year-over-year from $178.1 million in Q1 2025, and up 700.71% quarter-over-quarter from -$141000.0 in Q4 2025.
Tectonic Therapeutic (TECX) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Tectonic Therapeutic (TECX) has reported Cash from Financing Activities for 10 consecutive years, with $847000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 99.52% year-over-year to $847000.0; the TTM figure through Mar 2026 stood at -$3.9 million (down 101.12% YoY), while the FY2025 annual figure was $173.4 million, up 0.96% from the prior year.
- Cash from Financing Activities improved to $847000.0 in Q1 2026 per TECX's latest filing, from -$141000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $179.7 million in Q2 2024 and bottomed at -$6.3 million in Q3 2024.
- Historically, Cash from Financing Activities has averaged $22.3 million across 5 years, with a median of $1000.0 in 2022.
- On a YoY basis, Cash from Financing Activities climbed as much as 57747.46% in 2023 and fell as far as 32500.0% in 2023.
- Tectonic Therapeutic's Cash from Financing Activities stood at $59000.0 in 2022, then soared by 57747.46% to $34.1 million in 2023, then tumbled by 103.13% to -$1.1 million in 2024, then jumped by 86.81% to -$141000.0 in 2025, then jumped by 700.71% to $847000.0 in 2026.
- Business Quant data shows TECX's Cash from Financing Activities at $847000.0 in Q1 2026, -$141000.0 in Q4 2025, and -$457000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Tectonic Therapeutic | 671.50 Mn | 671.50 Mn | - | 11.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.68 Mn |
| Jun 30, 2026 | 11.68 Mn |
| Mar 31, 2026 | 847,000.00 |
| Mar 31, 2026 | 847,000.00 |
| Dec 31, 2025 | -141,000.00 |
| Dec 31, 2025 | -141,000.00 |
| Sep 30, 2025 | -457,000.00 |
| Sep 30, 2025 | -457,000.00 |
| Jun 30, 2025 | -4.17 Mn |
| Jun 30, 2025 | -4.17 Mn |
| Mar 31, 2025 | 178.12 Mn |
| Mar 31, 2025 | 178.12 Mn |
| Dec 31, 2024 | -1.07 Mn |
| Dec 31, 2024 | -1.07 Mn |
| Sep 30, 2024 | -6.29 Mn |
| Sep 30, 2024 | -6.29 Mn |
| Jun 30, 2024 | 179.74 Mn |
| Jun 30, 2024 | 179.74 Mn |
| Mar 31, 2024 | -668,000.00 |
| Mar 31, 2024 | -668,000.00 |